Drug company GlaxoSmithKline is setting up a US$25-million, five-year collaboration with the Harvard Stem Cell Institute in Cambridge, Massachusetts. The money will support research as well as a staff exchange programme between the two partners.
Announced on 24 July, the programme is another sign of the pharmaceutical industry's growing interest in stem-cell research, once considered the domain of academics and small biotechnology companies.
The Harvard collaboration is also the latest in a spate of academic collaborations launched by the UK-based drug firm. On 21 July, the company unveiled its 'academic incubator' collaboration with the University of Cambridge, UK, which will give researchers in neuroscience and metabolic disorders a more direct role in the early clinical development of treatments for addiction and obesity.
Rights and permissions
About this article
Cite this article
GlaxoSmithKline cements interest in stem cells. Nature 454, 564 (2008). https://doi.org/10.1038/454564c
Published:
Issue Date:
DOI: https://doi.org/10.1038/454564c